Introducing the Eclipse XL1: Regeneration, Not Replacement.
The Eclipse XL1 is the first in a family of technologies designed to stimulate the body’s natural regenerative response offering new hope for patients with Short Bowel Syndrome (SBS) and beyond.
The Eclipse XL1
The Eclipse XL1 is an entirely mechanical and repeatable approach designed to grow healthy intestinal tissue 2-3x longer within 2-3 weeks. Early studies have shown that new tissue has begun to function and absorb nutrients equally (or greater) than existing healthy intestinal tissue.
Featured In
Our Inspiration
On the Path from Lab to Life.
Across several clinical disciplines such as bone lengthening and skin expansion, it has been proven that controlled forces can cause the genesis of new functional tissue (through a process known as mechanotransduction).
In patients with Short Bowel Syndrome (SBS), the small intestine is typically too short to absorb life-sustaining nutrients from their diet. The Eclipse XL1 is a small “spring-like” device that is safely placed inside of the remaining intestine. With controlled force, the natural function (expansion and contraction) of the intestine works against the resistance of the Eclipse XL1.
Over the course of the next 2-3 weeks after placement, patients will eat and go about their daily routine whilst the Eclipse XL1 works to expand healthy tissue, revolutionizing the way we treat Short Bowel Syndrome (SBS).
Three Ways We Enable Healing.
Our regenerative solutions are built around three core techniques that can be applied across the GI tract, each designed to support tissue growth, closure, or stabilization in ways that reduce the need for invasive surgery.
Distraction Enterogenesis
Tissue Approximation
Anchoring
Stimulating tissue growth through mechanical lengthening.
Bringing tissue edges together to enable natural healing—particularly post-EMR or after resection.
Creating temporary, reversible holds in GI tissue to support stents, coils, and other devices.
Globally Recognized Innovation
Our work is guided by the world’s leading experts in pediatric surgery and gastrointestinal care. The Eclipse XL1 is the result of over a decade of rigorous research and development, including extensive preclinical testing and collaboration with top-tier academic institutions such as UCLA, Stanford, Cincinnati Children’s, and Boston Children’s Hospital.
To date, our technology and findings have been featured in more than 20+ peer-reviewed publications and serve as the foundation for future innovations in regenerative GI therapy.
Intestinal Tissue Regeneration
Early trial results illustrate 2-3x growth within 2-3 weeks of device placement.
For patients with Short Bowel Syndrome (SBS), current treatment options often involve lifelong IV nutrition, limited medications, and invasive surgical procedures. The Eclipse XL1 is designed to stimulate new intestinal growth offering patients the potential to increase absorption, reduce dependence on parenteral nutrition, and improve long-term outcomes.
Naturally Passing & Completely Repeatable
The Eclipse XL1 is designed for safe, controlled placement with minimal disruption to daily life. Over the course of 2-3 weeks, the device facilitates tissue lengthening and then passes naturally through the digestive tract eliminating the need for retrieval procedures. The process can be safely repeated to support additional growth as needed.
Healing from Within Starts Here
We believe the future of gastrointestinal care lies in regeneration, not restriction. With the Eclipse XL1, we’re helping patients grow what was once lost, reduce their dependence on invasive care, and move toward fuller, more independent lives.